(Nasdaq:TTNP) Titan Pharmaceuticals, Inc. common stock Ends Down After Wild 13.89% Swing

Titan Pharmaceuticals, Inc. common stock (Nasdaq:TTNP)

November 16th, 2018
Titan Pharmaceuticals, Inc. common stock fell $0.01 Friday which equals a 3.27% drop, closing at $0.39. Titan Pharmaceuticals, Inc. common stock swung 13.89% between high and low. While the stock did drop today, remember that it is still trading at 129% of its 52 week low of $0.17. In addition to the stock finishing lower, the trading volumes were only 30% of normal which could be an indication of investor uncertainty. Be aware that the Piotroski Score1 is calculated to be 2, which is very low as the scale goes from 0-9. This is considered to be a weak score in terms of financial strength.

TTNP was outperformed by the rest of the Healthcare sector which went up 0.94%.

Market Sectors

The market sectors were mixed Friday with a majority of the sectors trending up. Real Estate saw the biggest increase of the day (1.36%), while Consumer Discretionary saw the biggest drop (0.54%). Healthcare has seen the biggest year-to-date gain at 10%. The biggest loss this year has been the Communication Services sector declining 11%.

Real Estate saw the biggest turnaround from its 5-day performance of -0.39%, as it went up 1.36%.

Sector Breakdown

  • Real Estate went up with a 1.36% change.
  • Utilities went up with a 1.31% change.
  • Energy went up with a 1.10% change.
  • Materials went up with a 0.95% change.
  • Healthcare went up with a 0.94% change.
  • Consumer Staples went up with a 0.22% change.
  • Financials went up with a 0.10% change.
  • Industrials went down with a -0.03% change.
  • Information Technology went down with a -0.11% change.
  • Communication Services went down with a -0.39% change.
  • Consumer Discretionary went down with a -0.54% change.

Titan Pharmaceuticals is based in California, United States of America.

Titan Pharmaceuticals, Inc. common stock Info

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson’s disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

All amounts in USD unless otherwise indicated

(1) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Titan Pharmaceuticals, Inc. common stock’s score is 2), and 9 is the best.

TTNP daily update

TTNP daily update
TTNP daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.